yl)arylakan-2-ols (also called 9-aralkyladenines, or ARADS) wherein R is 3-CH_3 in its simplest form. R can also be can equal to: 2-$CH_2CH_2CH_3$; 3-CH_2CH_3; 2,3, or 4-CH_3; or H.--

In the Claims

Please cancel claim 16.

Please amend the following claims

5. The method of claim 1, wherein the inhibitor is erythrohydroxynonyl adenine. [EHNA].

6. The method of claim 1, where the inhibitor is (2S,3R)-3(6-aminopurin-9-yl)arylakan-2-ols [ARADS].

15. A pharmaceutical composition used for the treatment or preventing of systemic inflammatory response syndromes (SIRS), said composition comprising an amount of an inhibitor of adenosine deaminase sufficient to inhibit up to 100% of adenosine deaminase activity when administered for no more than 3 consecutive days in the form of a pharmaceutical preparation comprising a pharmaceutically acceptable carrier.

Remarks

I. Status of the Claims

Claim 16 is cancelled reserving the right to prosecute it in a continuing application.

Claims 5-6 and 15 are amended.

Claims 1-15 are pending.

II. Claim Amendments

Claim 16 is cancelled as not in U.S. format.

Claims 5-6 and 15 are amended.

III. An Oath Showing Priority to PCT/US001/13987 and U.S. Ser. No. 09/317,678 is Already of Record

The oath requested by the examiner is already of record. A copy is enclosed.

The present application was filed under 1.53(b) not 371.

IV. An Information Disclosure Statement was Filed September 3, 2002

V. The Variable R Is Exemplified

Those of skill in the art would know that n can equal 0, 1, 2, 3 or 4 and R can be equal to: 2-$CH_2CH_2CH_3$; 3-CH_2CH_3; 2,3, or 4-CH_3; or H. This is from Pragnacharyulu (2000) *J. Med. Chem.* 43: 4694-4700. The FIG. 12 legend rather than the FIG. is amended. Applicant realizes chemical formulas can optionally be put in the specification instead of the FIGS. but does not want to change them at this point because formal drawings were already made.

VI. A Terminal Disclaimer is Enclosed

Although applicant disagrees that a terminal disclaimer over U.S. Patent No. 6,103,702 is required, to move this case toward allowance, a terminal disclaimer is enclosed.

VII. Ryder Does Not Disclose all Elements of Claim 15

Claim 15 was rejected as anticipated in Ryder, but Ryder does not specify characteristics of the composition, that it will inhibit "up to 100% of adenosine deaminase activity when administered for no more than 3 consecutive days." Therefore, applicant requests allowance of claim 15. If this is not possible, to move the case toward allowance, please cancel claim 15.

VIII. Other Issues

The corrected FIGS. are being sent in a separate communication to the Office Draftsperson.

IX. Summary and Conclusion

For the reasons stated above, reconsideration and allowance of all pending claims is requested.

No other fees are believed due at this time, however, please charge any additional deficiencies or credit any overpayments to deposit account number 10-0435 with reference to our attorney docket number (27726/92990).

Respectfully submitted,

Alice O. Martin
Registration No. 35,601

September 13, 2002

Page 9, lines 27-28

[FIG. 12 shows a general chemical structure of (2S,3R)-3(6-aminopurin-9-yl)arylakan-2-ols (also called 9-aralkyladenines, or ARADS).]

FIG. 12 shows a general chemical structure of (2S,3R)-3(6-aminopurin-9-yl)arylakan-2-ols (also called 9-aralkyladenines, or ARADS) wherein R is 3-CH_3 in its simplest form. R can also be can equal to: 2-$CH_2CH_2CH_3$; 3-CH_2CH_3; 2,3, or 4-CH_3; or H.

MARKED UP VERSION OF THE CLAIMS
SERIAL NO. 09/994,923
OUR REF. NO. 21726/92990

WHAT IS CLAIMED IS:

1. A method for treating or preventing adverse consequences of systemic inflammatory response syndrome (SIRS) in a mammal in need of the treatment, said method comprising administering to said mammal an amount of an inhibitor of adenosine deaminase (ADA) effective to ameliorate symptoms of the syndrome, wherein said effective amount causes inhibition of up to 100% of the normal values of ADA and the inhibition is delivered locally.

2. The method of claim 1, wherein the symptoms of the syndrome comprise an inflammatory response and to ameliorate the symptom is to decrease it.

3. The method of claim 1, wherein the symptoms of the syndrome comprise oxygen free radical-mediated tissue injury, and to ameliorate the symptom is to reduce it.

4. The method of claim 1, wherein the inhibitor is pentostatin.

5. The method of claim 1, wherein the inhibitor is erythrohydroxynonyl adenine. [EHNA].

6. The method of claim 1, where the inhibitor is (2S,3R)-3(6-aminopurin-9-yl)arylakan-2-ols [ARADS].

7. The method of claim 1, wherein the symptoms of the syndrome comprise tissue perfusion maldistribution, and to ameliorate the symptom is to redistributed appropriately.

8. The method of claim 1, wherein the symptoms of the syndrome comprise increased vascular leakage, and to ameliorate the symptom is to reduce it.

9. The method of claim 1, wherein SIRS results from non-infectious origins.

10 The method of claim 1, wherein treatment is for no more than 3 consecutive days.

11. The method of claim 10, wherein the treatment is for periods of no more than 72 consecutive hours.

12. The method of claim 1, wherein the symptoms of the syndrome comprise an imbalance between pro-inflammatory and anti-inflammatory responses, and the method ameliorates the symptoms by restoring balance.

13. The method of claim 1, wherein the symptoms include multiple organ failure, and the method reduces the number or extent of organ failures.

14. The method of claim 1, wherein the symptoms comprise excessive extravasation of fluid and vascular proteins (capillary leakage), and the method reduces capillary leakage.

15. A pharmaceutical composition used for the treatment or preventing of systemic inflammatory response syndromes (SIRS), said composition comprising an amount of an inhibitor of adenosine deaminase sufficient to inhibit up to 100% of adenosine deaminase activity when administered for no more than 3 consecutive days in the form of a pharmaceutical preparation comprising a pharmaceutically acceptable carrier.

[16. Use of an adenosine deaminase inhibitor to increase levels of adenosine locally and in a regionally selective manner in a mammal affected by an inflammatory condition.]